Caroline Liu1, Kathryn Foti2, Morgan E Grams2,1, Jung-Im Shin2, Elizabeth Selvin3. 1. Department of Medicine, Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2. Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 3. Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. eselvin@jhu.edu.
Abstract
BACKGROUND: The American Diabetes Association (ADA) recommends that treatment with metformin be considered for prevention of type 2 diabetes in persons with prediabetes. However, metformin use outside the setting of diagnosed diabetes in US adults is not well characterized. OBJECTIVE: To examine trends in self-reported prediabetes and treatment with metformin. We also compared characteristics of adults self-reported prediabetes who were vs. were not taking metformin. DESIGN: Cross-sectional analysis. PARTICIPANTS: Adults ≥ 20 years of age who participated in the 2005-2014 National Health and Nutrition and Examination Survey (NHANES), n = 28,461. APPROACH: We characterized trends in self-reported prediabetes and metformin use in this population. We used multiple logistic regression models to identify predictors of metformin use among adults with self-reported prediabetes. All analyses accounted for the weighted complex survey design to generate nationally representative estimates. KEY RESULTS: The prevalence of self-reported prediabetes increased from 5.1% in 2005-2006 to 7.4% in 2013-2014 (P-for-trend < 0.001). In persons with self-reported prediabetes, metformin use increased, from 2.4 to 8.3% (P-for-trend = 0.013). Adults who were taking metformin were more likely to be obese and to report trying to lose weight in the past year. CONCLUSIONS: Self-reported prediabetes has increased in the past decade. Metformin use in the setting of prediabetes has also increased but remains relatively uncommon at 8% in adults who self-report prediabetes, despite current clinical recommendations.
BACKGROUND: The American Diabetes Association (ADA) recommends that treatment with metformin be considered for prevention of type 2 diabetes in persons with prediabetes. However, metformin use outside the setting of diagnosed diabetes in US adults is not well characterized. OBJECTIVE: To examine trends in self-reported prediabetes and treatment with metformin. We also compared characteristics of adults self-reported prediabetes who were vs. were not taking metformin. DESIGN: Cross-sectional analysis. PARTICIPANTS: Adults ≥ 20 years of age who participated in the 2005-2014 National Health and Nutrition and Examination Survey (NHANES), n = 28,461. APPROACH: We characterized trends in self-reported prediabetes and metformin use in this population. We used multiple logistic regression models to identify predictors of metformin use among adults with self-reported prediabetes. All analyses accounted for the weighted complex survey design to generate nationally representative estimates. KEY RESULTS: The prevalence of self-reported prediabetes increased from 5.1% in 2005-2006 to 7.4% in 2013-2014 (P-for-trend < 0.001). In persons with self-reported prediabetes, metformin use increased, from 2.4 to 8.3% (P-for-trend = 0.013). Adults who were taking metformin were more likely to be obese and to report trying to lose weight in the past year. CONCLUSIONS: Self-reported prediabetes has increased in the past decade. Metformin use in the setting of prediabetes has also increased but remains relatively uncommon at 8% in adults who self-report prediabetes, despite current clinical recommendations.
Entities:
Keywords:
diabetes; epidemiology; guidelines; population health; prevention
Authors: Samuel Klein; David B Allison; Steven B Heymsfield; David E Kelley; Rudolph L Leibel; Cathy Nonas; Richard Kahn Journal: Diabetes Care Date: 2007-03-14 Impact factor: 19.112
Authors: Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright Journal: J Am Coll Cardiol Date: 2017-11-13 Impact factor: 24.094
Authors: Mohammed K Ali; Kai McKeever Bullard; Sharon Saydah; Giuseppina Imperatore; Edward W Gregg Journal: Lancet Diabetes Endocrinol Date: 2018-02-27 Impact factor: 32.069
Authors: William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan Journal: N Engl J Med Date: 2002-02-07 Impact factor: 91.245
Authors: Bethany Warren; James S Pankow; Kunihiro Matsushita; Naresh M Punjabi; Natalie R Daya; Morgan Grams; Mark Woodward; Elizabeth Selvin Journal: Lancet Diabetes Endocrinol Date: 2016-11-16 Impact factor: 32.069
Authors: Elizabeth Selvin; Dan Wang; Alexandra K Lee; Richard M Bergenstal; Josef Coresh Journal: Ann Intern Med Date: 2017-10-24 Impact factor: 25.391